DarioHealth reports Q4 revenue $7.6M, consensus $7.39M

“Our strategic initiatives yielded remarkable financial improvements throughout 2024 in both our top and bottom line. We are already seeing this positive trajectory continue into 2025. For the full year of 2024, total revenue reached $27.0 million, representing a 32.9% increase from $20.4 million in 2023. Additionally, recurring revenues from our B2B2C business-employers and health plans-grew significantly, reaching $5.6 million in the fourth quarter of 2024, compared to $1.1 million in the fourth quarter of 2023, representing a 398% year-over-year increase. This growth was driven by the continued expansion of our core B2B2C business and the successful integration of Twill. While we are excited about our top line growth, profitability cannot be achieved through revenue growth alone. With a dual focus on revenue and expense efficiency, we implemented focused cost-management strategies that led to a 35% reduction in our operating loss from the first quarter of 2024 to the fourth quarter of 2024 without impairing our growth ambitions. Looking ahead, we anticipate an additional 20% reduction in operating expenses by the fourth quarter of 2025, which we believe can further strengthen our financial position. With these efficiencies and continued business momentum, we believe the Company is on track to achieve an operational cash flow breakeven run rate by the end of 2025,” said Erez Raphael, CEO of Dario.